{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ranibizumab+2.0mg",
    "query": {
      "intervention": "ranibizumab 2.0mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ranibizumab+2.0mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T10:21:26.091Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01926977",
      "title": "Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 0.5mg",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2.0mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arshad Khanani",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2013-09",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-03-03",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 1,
      "location_summary": "Reno, Nevada",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01926977"
    },
    {
      "nct_id": "NCT00533520",
      "title": "Evaluation of Dosing Interval of Higher Doses of Ranibizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brandon G. Busbee, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "50 Years to 95 Years"
      },
      "enrollment_count": 37,
      "start_date": "2007-09",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-11-25",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00533520"
    },
    {
      "nct_id": "NCT01884597",
      "title": "Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "PCV",
        "Polypoidal Choroidal Vasculopathy"
      ],
      "interventions": [
        {
          "name": "high-dose ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hawaii Pacific Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "25 Years to 95 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-11",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-10-09",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 3,
      "location_summary": "Honolulu, Hawaii • ‘Aiea, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "‘Aiea",
          "state": "Hawaii"
        },
        {
          "city": "‘Aiea",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01884597"
    },
    {
      "nct_id": "NCT01334879",
      "title": "High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Radiation Retinopathy"
      ],
      "interventions": [
        {
          "name": "ranibizumab 2.0 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The New York Eye Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-05",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2014-10-02",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01334879"
    },
    {
      "nct_id": "NCT01205035",
      "title": "High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinal Diseases",
        "Telangiectasis"
      ],
      "interventions": [
        {
          "name": "ranibizumab 2.0mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Center of Northern Colorado, P.C.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2010-10",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2015-04-10",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 1,
      "location_summary": "Fort Collins, Colorado",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01205035"
    },
    {
      "nct_id": "NCT00509795",
      "title": "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aflibercept injection (VEGF Trap-Eye, BAY86-5321)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1217,
      "start_date": "2007-08",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2012-12-28",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 176,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509795"
    },
    {
      "nct_id": "NCT00440609",
      "title": "Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinically Significant Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Philip J. ferrone, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-08-02",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 2,
      "location_summary": "Great Neck, New York • Hauppauge, New York",
      "locations": [
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Hauppauge",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440609"
    },
    {
      "nct_id": "NCT01025232",
      "title": "A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age Related Macular Degeneration",
        "Choroidal Neovascular Membrane",
        "Subfoveal Neovascular Age-Related Macular Degeneration",
        "Macular Degeneration",
        "Wet Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David M. Brown, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2009-12",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • The Woodlands, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01025232"
    },
    {
      "nct_id": "NCT01292798",
      "title": "Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Retina Consultants",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2011-03",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-22",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 5,
      "location_summary": "Bakersfield, California • Oxnard, California • Santa Barbara, California + 2 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01292798"
    },
    {
      "nct_id": "NCT01469156",
      "title": "Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Polypoidal Choroidal Vasculopathy"
      ],
      "interventions": [
        {
          "name": "ranibizumab 0.5 or 2.0 mg/0.05 cc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southeast Retina Center, Georgia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-09",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2022-12-12",
      "last_synced_at": "2026-09-23T10:21:26.091Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01469156"
    }
  ]
}